Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 321

1.

HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.

Zhang H, Ren G, Wang X, Zhao J, Yao H, Bai Y, Bo W.

Breast Cancer Res Treat. 2012 Jul;134(2):743-9. doi: 10.1007/s10549-012-2101-x. Epub 2012 Jun 8.

PMID:
22678158
2.

Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.

Murthy SS, Sandhya DG, Ahmed F, Goud KI, Dayal M, Suseela K, Rajappa SJ.

Indian J Pathol Microbiol. 2011 Jul-Sep;54(3):532-8. doi: 10.4103/0377-4929.85087.

3.
4.

Assessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining.

Mostafa NA, Eissa SS, Belal DM, Shoman SH.

J Egypt Natl Canc Inst. 2011 Mar;23(1):41-6. doi: 10.1016/j.jnci.2011.07.006. Epub 2011 Sep 8.

5.

HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival.

Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML.

Mol Diagn. 2000 Sep;5(3):199-207.

PMID:
11070154
6.

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51.

7.

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.

Wang S, Hossein Saboorian M, Frenkel EP, Haley BB, Siddiqui MT, Gokaslan S, Hynan L, Ashfaq R.

Mod Pathol. 2002 Feb;15(2):137-45.

8.

Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?

Sauer T, Wiedswang G, Boudjema G, Christensen H, Karesen R.

APMIS. 2003 Mar;111(3):444-50.

PMID:
12752225
9.
10.

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.

Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G.

Cancer. 2001 Dec 15;92(12):2965-74.

PMID:
11753973
11.

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.

D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.

Am J Surg Pathol. 2010 Apr;34(4):575-81. doi: 10.1097/PAS.0b013e3181d65639.

PMID:
20216378
12.

Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.

Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C.

Histopathology. 2005 Apr;46(4):431-41.

PMID:
15810955
13.
14.
17.

HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M.

Int J Oncol. 1999 Apr;14(4):663-71.

PMID:
10087312
18.

Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.

Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, Piccart MJ, Larsimont D.

Clin Cancer Res. 2005 Jun 15;11(12):4393-9.

19.

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.

Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, Park SY.

J Clin Pathol. 2008 Mar;61(3):317-21. Epub 2007 Aug 30.

PMID:
17761736

Supplemental Content

Support Center